评估IL-1对抗剂对下垂体功能的影响
Fadime Aktas Koc1, Baris Sariakcali2, Ali Sahin3
1Department of Internal Medicine, Sivas Numune Hospital, Sivas, 58140, Türkiye, saglik.gov.tr.
International journal of endocrinology
|January 14, 2026
概括
干白素-1 (IL-1) 抑制剂在家族地中海热 (FMF) 患者中没有引起显著的垂体或上腺功能不全. 需要进一步的研究,以充分了解IL-1对抗剂对垂体功能的影响.
科学领域:
- 内分泌学 在内分泌学.
- 类风湿病学 类风湿病学
- 遗传学 是一个遗传学.
背景情况:
- 家庭地中海热 (FMF) 是一种由MEFV基因突变引起的自身炎症性疾病,导致IL-1β分泌失调和炎症.
- IL-1抑制剂正在作为FMF的治疗方法出现,但它们对内分泌功能的影响需要研究.
研究的目的:
- 评估IL-1抑制剂对FMF患者垂体功能的影响.
- 为了比较用IL-1抑制剂治疗的FMF患者的脑垂体激素水平与单独服用胆固醇的患者.
主要方法:
- 在Sivas Cumhuriyet大学医院进行了一项比较研究.
- 在使用IL-1抑制剂≥6个月的FMF患者中测量了脑下垂体和内分泌激素水平,以及对照组使用胆固醇.
- 排除标准包括皮质类固醇使用,癌症和血液透析;对皮质醇缺乏进行了Synacthen测试.
主要成果:
- 两组之间没有观察到TSH,ACTH,皮质醇,LH,雌激素,IGF-1或PRL水平的显著差异.
- 在仅服用胆固醇的组中,FSH和GH水平更高.
- 在IL-1抑制剂组中,总丸激素水平较高.
结论:
- 在FMF患者中,IL-1抑制剂并没有导致显著的上腺或垂体缺陷.
- 虽然IL-1影响激素分泌,但观察到的激素差异的临床意义需要进一步研究.
相关概念视频
Hypothalamic-Pituitary Axis
65.4K
The response to stress—be it physical or psychological, acute or chronic—involves activation of the Hypothalamic-Pituitary-Adrenal (HPA) axis. The HPA axis is part of the neuroendocrine system because it involves both neuronal and hormonal communication. Its function is to regulate homeostatic systems—metabolic, cardiovascular, and immune—providing the necessary means to respond to a stressor.
65.4K
Hormones of the Pituitary Gland
9.4K
The small, pea-sized pituitary gland is located at the base of the brain. It is crucial in regulating various bodily functions, from growth to reproduction. The gland is divided into the anterior lobe and the posterior lobe. The secretory cell clusters in the pars distalis of the anterior pituitary lobe are controlled by hypothalamic regulators and synthesize six primary hormones.
The most abundantly secreted hormone from the anterior lobe is the growth hormone, which controls overall growth by...
The most abundantly secreted hormone from the anterior lobe is the growth hormone, which controls overall growth by...
9.4K
Indirect-Acting Cholinergic Agonists: Pharmacological Actions
1.4K
Indirect-acting cholinergic agonists, also known as anticholinesterases, exert their pharmacological effects by enhancing cholinergic transmission in various body parts, including the neuromuscular junction, autonomic cholinergic synapses, and the brain.
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
1.4K
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
457
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
457
Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers
1.4K
α-Adrenergic antagonists, known as α-blockers, exert their effects by inhibiting α-adrenoceptors, leading to specific physiological actions. α1-blockers and α2-blockers have distinct pharmacological actions and therapeutic applications.
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally,...
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally,...
1.4K
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
438
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
438


